Research Progress on the Role of M6A Methylation Modification in the Genesis and Development of GC

  • Wenjun Jiang College of Medical Technology, Shaanxi University of Chinese Medicine
  • Ya Li College of Medical Technology, Shaanxi University of Chinese Medicine/Clinical laboratory center, Xi’an People’s Hospital (Xi’an Fourth Hospital)
Keywords: GC; m6A;ALKBH5; Epigenetics


Modifcation of M6ARNAmethylation is the most prevalent form of RNAediting in eukaryotic organisms. The m6A-methylated regulatory protein is intimately associated with biological processes, including GC proliferation, invasion, and metastasis. This protein is anticipated to serve as a target for the clinical treatment of GC in the future. This comprehensive review delineates the most recent advance-ments and clinical implications of m6Aaberrant modifcation in GC, aiming to furnish a novel research avenue for the exploration of GC’s future direction.


[1] Sung, H., et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in

185 Countries. CA Cancer J Clin, 2021. 71(3): p. 209-249.

[2] Zong, L., et al., The challenge of screening for early GC in China. Lancet, 2016. 388(10060): p. 2606.

[3] Asaka, M., et al., GC deaths by age group in Japan: Outlook on preventive measures for elderly adults. Cancer Sci, 2020. 111(10): p.3845-3853.

[4] Wang, S., et al., Global and national trends in the age-specific sex ratio of esophageal cancer and GC by subtype. Int J Cancer,

2022. 151(9): p. 1447-1461.

[5] Wang, F., et al., Family history of malignant tumor is a predictor of GC prognosis: Incorporation into a nomogram. Medicine (Baltimore), 2022. 101(35): p. e30141.

[6] Usui, Y., et al., Helicobacter pylori, Homologous-Recombination Genes, and GC. N Engl J Med, 2023. 388(13): p. 1181-1190.

[7] Comprehensive molecular characterization of gastric adenocarcinoma. Nature, 2014. 513(7517): p. 202-9.

[8] Nguyen, P.H., et al., Characterization of Biomarkers of Tumorigenic and Chemoresistant Cancer Stem Cells in Human Gastric Carcinoma. Clin Cancer Res, 2017. 23(6): p. 1586-1597.

[9] Lander, E.S., et al., Initial sequencing and analysis of the human genome. Nature, 2001. 409(6822): p. 860-921.

[10] Guan, K., et al., Expression Status And Prognostic Value Of M6A-associated Genes in GC. J Cancer, 2020. 11(10): p. 3027-3040.

[11] Liang, Z., et al., Epigenetic N6-methyladenosine modification of RNA and DNA regulates cancer. Cancer Biol Med, 2020. 17(1): p.


[12] Melstrom, L. and J. Chen, RNA N(6)-methyladenosine modification in solid tumors: new therapeutic frontiers. Cancer Gene Ther,

2020. 27(9): p. 625-633.

[13] Weng, H., H. Huang, and J. Chen, RNA N (6)-Methyladenosine Modification in Normal and Malignant Hematopoiesis. Adv Exp

Med Biol, 2019. 1143: p. 75-93.

[14] Mauer, J. and S.R. Jaffrey, FTO, m(6) A(m), and the hypothesis of reversible epitranscriptomic mRNA modifications. FEBS Lett,

2018. 592(12): p. 2012-2022.

[15] Meyer, K.D. and S.R. Jaffrey, The dynamic epitranscriptome: N6-methyladenosine and gene expression control. Nat Rev Mol Cell

Biol, 2014. 15(5): p. 313-26.

[16] Wang, N., et al., METTL3-Mediated ADAMTS9 Suppression Facilitates Angiogenesis and Carcinogenesis in GC. Front Oncol,

2022. 12: p. 861807.

[17] Ji, G., X. Wang, and H. Xi, METTL3-mediated m(6)A modification of lncRNA SNHG3 accelerates GC progression by modulating miR-186-5p/cyclinD2 axis. Int J Immunopathol Pharmacol, 2023. 37: p. 3946320231204694.

[18] Li, R., et al., miR-181-5p/KLHL5 Promoted Proliferation and Migration of GC Through Activating METTL3-Mediated m6A Process. Mol Biotechnol, 2023.

[19] Liu, N., C. Zhang, and L. Zhang, WTAP-Involved the m6A Modification of lncRNA FAM83H-AS1 Accelerates the Development

of GC. Mol Biotechnol, 2023.

[20] Miao, R., et al., KIAA1429 regulates cell proliferation by targeting c-Jun messenger RNA directly in GC. J Cell Physiol, 2020.

235(10): p. 7420-7432.

[21] Wang, X.K., et al., METTL16 promotes cell proliferation by up-regulating cyclin D1 expression in GC. J Cell Mol Med, 2021.

25(14): p. 6602-6617.

[22] Fan, H.N., et al., METTL14-mediated m(6)A modification of circORC5 suppresses GC progression by regulating miR-30c-2-3p/

AKT1S1 axis. Mol Cancer, 2022. 21(1): p. 51.

[23] Liu, X., et al., The m6A methyltransferase METTL14 inhibits the proliferation, migration, and invasion of GC by regulating the

PI3K/AKT/mTOR signaling pathway. J Clin Lab Anal, 2021. 35(3): p. e23655.

[24] Zhu, Y., et al., Demethylase FTO enhances the PI3K/Akt signaling to promote GC malignancy. Med Oncol, 2023. 40(5): p. 130.

[25] Zhou, Y., et al., N6-methyladenosine demethylase FTO promotes growth and metastasis of GC via m(6)A modification of caveolin-1 and metabolic regulation of mitochondrial dynamics. Cell Death Dis, 2022. 13(1): p. 72.

[26] Hu, Y., et al., Demethylase ALKBH5 suppresses invasion of GC via PKMYT1 m6A modification. Mol Cancer, 2022. 21(1): p. 34.

[27] Chen, W., et al., PLAGL2 promotes Snail expression and GC progression via UCA1/miR-145-5p/YTHDF1 axis. Carcinogenesis, 2023. 44(4): p. 328-340.

[28] Bai, X., et al., Loss of YTHDF1 in gastric tumors restores sensitivity to antitumor immunity by recruiting mature dendritic cells. J

Immunother Cancer, 2022. 10(2).

[29] Shen, X., et al., YTHDF2 Inhibits GC Cell Growth by Regulating FOXC2 Signaling Pathway. Front Genet, 2020. 11: p. 592042.

[30] Ji, R., et al., IGF2BP2-meidated m(6)A modification of CSF2 reprograms MSC to promote GC progression. Cell Death Dis, 2023.

14(10): p. 693.

[31] Wang, Y., et al., METTL3 promotes drug resistance to oxaliplatin in GC cells through DNA repair pathway. Front Pharmacol,

2023. 14: p. 1257410.

[32] Tang, B., et al., N(6)-methyladenosine (m(6)A) writer KIAA1429 accelerates GC oxaliplatin chemoresistance by targeting

FOXM1. J Cancer Res Clin Oncol, 2023. 149(8): p. 5037-5045.

[33] Zhu, Z., et al., m(6)A Methyltransferase KIAA1429 Regulates the Cisplatin Sensitivity of GC Cells via Stabilizing FOXM1

mRNA. Cancers (Basel), 2022. 14(20).

[34] Liu, Y. and M. Da, Wilms tumor 1 associated protein promotes epithelial mesenchymal transition of GC cells by accelerating

TGF-β and enhances chemoradiotherapy resistance. J Cancer Res Clin Oncol, 2023. 149(7): p. 3977-3988.

Review Article